| Objective:To investigate the expression of WW domain-containing oxidoreductase (WWOX) and fragile histidine triad (FHIT) in childhood leukemia, to analyze the relationship between WWOX, FHIT and childhood Leukemia, to discuss the role of WWOX, FHIT in the pathogenesis of childhood leukemia.Methods:51 cases of children with leukemia from January 2009 to March 2011 were collected as the leukemia group,10 cases of children without leukemia were collected from the People’s Hospital of Hunan Province during the same period as the control group, the expression of WWOXmRNA and FHITmRNA were decected from the bone marrow mononuclear cells (BMMCs) of two goups. Results:1.The positive rate of WWOXmRNA in the leukemia group was significantly less than that of the control group (31.37%vs 100.00%, P< 0.01).2.The positive rate of WWOXmRNA in the remission group was significantly less than that of the control group (3.33%vs 100.00%, P 0.01).3.In the leukemia group, no significant difference was found in the positive rate of WWOXmRNA between groups differ from age, sex, leukemia type, treatment phase and tumor load (P> 0.05).4.The positive rate of FHITmRNA in the leukemia group was significantly less than that of the control group (54.90%vs 100.00%, P<5.No significant difference was found between the positive rate of FHITmRNA in the remission group with the control group (66.67%vs 100.00%, P>0.05).6.In the leukemia group, no significant difference was found in the positive rate of FHITmRNA between groups differ from age, sex, leukemia type, treatment phase (P> 0.05). 7.In the leukemia group, the positive rate of FHITmRNA in the high tumor load group was significantly lower than that of the low tumor load group (33.33%vs 66.67%, P<0.05).8.Neither WWOXmRNA nor FHITmRNA was detected from 15 patients in the leukemia group.Conclusion:1.Children with leukemia had a low expression of WWOXmRNA and FHITmRNA.2.There was no significant difference in the positive rate of WWOXmRNA among leukemia children differ from sex, leukemia type, treatment phase and tumor load.3.There was no significant difference in the positive rate of FHITmRNA among leukemia children differ from sex, leukemia type, treatment phase.4.The positive rate of FHITmRNA in the high tumor load leukemia children was significantly lower than that of the low tumor load leukemia children. Objective:To investigate Zebularine(Zeb) on expression of WWOX, FHIT in Jurkat and K562, to analyze the mechanism of Zeb on WWOX and FHIT, to discuss the significance of Zeb in the treatment in leukemia.Methods:According to the concentration of Zeb, Jurkat and K562 were divided into 3 groups respectively, including the control group, the 250μM group (Zeb eventually concentration for 250μM)and the 500μM group (for Zeb eventually concentration 500μM).48 hours after zeb intervention, nested PCR was used to detect WWOXmRNA and FHITmRNA, Western Blot was used to detect the protein of WWOX and FHIT.Results:1.For K562, WWOXmRNA expression was not detected in the control group, and it was detected in the 250μM group and the 500μM group. WWOXmRNA expression of the 250μM group was not significantly higher than that of the control group (P>0.05). WWOXmRNA expression of the 500μM group was significantly higher than that of the control group and the 250μM group (P< 0.01). 2.For Jurkat, WWOXmRNA expression of the control group and the 250μM group was not detected, WWOXmRNA expression of the 500μM group was detected (P<0.01).3.48 hours after zeb intervention, the protein of WWOX and FHIT expression of the 250μM group and the 500μM group was significantly higher than that of the control group (P<0.01), the protein of WWOX and FHIT expression of the 500μM group was significantly higher than that of the 250μM group (P<0.01).Conclusion:Zeb could upregulate WWOXmRNA, FHIT mRNA and the protein of WWOX and FHIT expression, and the effect had certain concentration dependence.. Objective:To investigate Impact of Zebularine on proliferation and apoptosis in K562 and Jurkat, to explore the suppressor mechanism of Zeb in leukemia, to explore the value of Zeb in the treatment in leukemia.Methods:According to the concentration of Zeb, Jurkat and K562 was respectively divided into three groups:the control group, the 250μM group (Zeb eventually concentration for 250μM) and the 500μM group (Zeb eventually concentration for 500μM). MTT kit was used to detect the OD570 of Jurkat and K562 12 hours,24 hours,36 hours,48 hours and 72 hours after zeb intervention, Cells forms were observed by inverted microscope 48 hours after zeb intervention, Annexin V/FITC kit and cell cycle immuosorbent detection kit were used to detect apoptosis of the two kinds of cells 48 hours after zeb intervention.Results:1.48 hours after zeb intervention, the OD570 of Jurkat and k562 decreased significantly with the increasing of concentration of zeb. 2.Cells forms were observed by inverted microscope 48 hours after zeb intervention, for control groups of Jurkat and K562, cells grew well and distributed clusterly. In the 250μM group, cells in group distribution were decreased and detracted. In the 500μM group, cells were detracted completely.3.48 hours after zeb intervention, the proportion of early apoptosis cells and apoptosis peak value of the 250μM group and the 500μM group were significantly higher than that of the control group (P< 0.01). Compared to the 250μM group, both proportion of early apoptosis cells and apoptosis peak value were higher in the 500μM group (P< 0.01)Conclusion:Zeb could inhibit proliferation and promote apoptosis of Jurkat and K562, and the effect had certain concentration dependence. |
PDF Full Text Request